{"id":"NCT02040766","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","briefTitle":"A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma","officialTitle":"A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, 12-Week Clinical Study to Assess the Efficacy and Safety of 80 or 160 mcg/Day of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Pediatric Patients 4 Through 11 Years of Age With Persistent Asthma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-12","primaryCompletion":"2016-02","completion":"2016-03","firstPosted":"2014-01-20","resultsPosted":"2018-02-12","lastUpdate":"2021-11-09"},"enrollment":628,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"Beclomethasone dipropionate BAI","otherNames":["BDP","breath-actuated inhaler"]},{"type":"DRUG","name":"Placebo BAI","otherNames":["breath-actuated inhaler"]},{"type":"DRUG","name":"albuterol/salbutamol 90 mcg","otherNames":["bronchodilators"]},{"type":"DRUG","name":"Beclomethasone dipropionate MDI","otherNames":["BDP","metered-dose inhaler","QVARÂ®"]},{"type":"DRUG","name":"Placebo MDI","otherNames":[]}],"arms":[{"label":"BDP 80 mcg BAI","type":"EXPERIMENTAL"},{"label":"BDP 160 mcg BAI","type":"EXPERIMENTAL"},{"label":"BDP 80 mcg MDI","type":"ACTIVE_COMPARATOR"},{"label":"BDP 160 mcg MDI","type":"ACTIVE_COMPARATOR"},{"label":"Placebo BAI and MDI","type":"PLACEBO_COMPARATOR"}],"summary":"This randomized, double-blind, double-dummy, placebo-controlled, parallel-group, 12-week study will evaluate the efficacy and safety of beclomethasone dipropionate (80 or 160 mcg/day) administered via breath-actuated inhaler (BAI) and metered-dose inhaler (MDI) in pediatric patients 4 through 11 years of age with persistent asthma, compared with placebo.\n\nPatients took 1 inhalation (with assistance from parents/guardians/caregivers, as needed) from each of 2 devices (BAI device followed by MDI device in that order) twice daily as per the double-dummy study design: 1 BAI treatment or placebo device and 1 MDI treatment or placebo device for a total of 2 inhalations each time.","primaryOutcome":{"measure":"Standardized Baseline-adjusted Trough Morning Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Effect Curve From Time 0 to 12 Weeks (AUEC(0-12wk))","timeFrame":"Day 1 (baseline), Weeks 2, 4, 8, 12","effectByArm":[{"arm":"Placebo BAI and MDI","deltaMin":2.62,"sd":0.744},{"arm":"BDP 80 mcg BAI","deltaMin":5.43,"sd":0.742},{"arm":"BDP 160 mcg BAI","deltaMin":3.25,"sd":0.732},{"arm":"BDP 80 mcg MDI","deltaMin":3.54,"sd":0.734},{"arm":"BDP 160 mcg MDI","deltaMin":3.71,"sd":0.734}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0063"},{"comp":"OG000 vs OG002","p":"0.5332"},{"comp":"OG000 vs OG003","p":"0.3649"},{"comp":"OG000 vs OG004","p":"0.2823"}]},"eligibility":{"minAge":"4 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":7},"locations":{"siteCount":102,"countries":["United States","Croatia","Mexico","Poland","Ukraine"]},"refs":{"pmids":["28710850"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":628},"commonTop":["Nasopharyngitis","Cough"]}}